Navigation Links
FDA Advisers Back Anemia Drugs for Kidney Patients
Date:10/19/2010

ents.

"The label should be adjusted, but I just don't think we have enough information to recommend a fixed dose," Dr. Judith Hochman, head of cardiology at NYU School of Medicine, told the AP.

The study published last spring, a meta-analysis of 27 trials that included more than 10,000 people who were given the erythropoiesis-stimulating agents (ESAs), found that those who took the drugs to achieve the highest blood hemoglobin targets had a 51 percent increased risk for stroke and a 33 percent increased risk for thrombosis, or blockage of an artery. The study, by an international group of experts, was published online May 3 in Annals of Internal Medicine.

The increased risk for death (9 percent) and serious cardiovascular events such as heart attacks (15 percent) did not reach statistical significance, the analysis found.

The FDA has acted to control the use of ESAs in the past, and the agency has added a "black box" warning of dangers to the drugs' labeling.

Last spring's study added emphasis to such moves, Dr. Ajay K. Singh, an associate professor of medicine at Harvard Medical School and a nephrologist at Brigham and Women's Hospital in Boston, told HealthDay at the time.

"This meta-analysis shows increased risk with no benefit," Singh said. "The supposed benefit is that ESAs improve quality of life and make people feel better. This study suggests that these drugs, used at considerable cost, don't show any benefit in terms of those endpoints."

ESAs cost Medicare $2 billion a year, Singh said, making them the most expensive drugs in terms of cost that the government has paid for.

Yet ESAs do have a role in treating some people with chronic kidney disease, despite their dangers, Singh said.

New FDA rules, put into effect earlier this year, require that Amgen, the company that markets the drugs, disseminate a guide informing all patients of the drugs' risks and that doctors discuss those
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. FDA Advisers Consider Approval of Genetically Modified Salmon
2. FDA Advisers Weigh Approval of Genetically Modified Salmon
3. FDA Advisers Divided on Whether to Ban Diet Drug Meridia
4. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
5. FDA to Broaden Disclosure on Advisers Conflicts of Interest
6. FDA Advisers Urge Stricter Regulation of Tanning Beds
7. Anemia Drugs Could Pose Threat to Some Kidney Patients
8. Stroke prevention study in children with sickle cell anemia, iron overload stopped early
9. OHSU joins forces with UO, Harvard to accelerate Fanconi anemia research
10. Anemia Drugs Hold Dangers for Kidney Patients
11. Anemia Harder to Treat in Black Children With Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Advisers Back Anemia Drugs for Kidney Patients
(Date:5/19/2013)... Healthcare leaders will gather at the ... Walt Disney World Swan and Dolphin in Orlando, Fla., ... care delivery and healthcare reform and implementation. , “Reform ... markets, with consolidation, efficiency and reduced payments ... Ebert, Amerinet president and CEO. “There is a real ...
(Date:5/19/2013)... 19, 2013 The muscles in the ... functionality and one of the biggest and most significant ... system. The peripheral system comprises of peripheral nerves that ... These nerves ensure that the limbs and hands, as ... these nerves get damaged due to trauma or physical ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 These ... for US, UK, Spain, Japan, Italy, Germany and ... the molecular diagnostics laboratory practice, as well as ... with significant market impact during the next five ... probe and biochip technologies, test formats, detection methodologies, ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Farming methods ... seed in the ground 10,000 years ago. Most recently, ... farm productivity by using genetically engineered seeds and by ... seeing a backlash to these techniques due to the ... chemicals and a corresponding surge in interest in organic, ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Agora Health Limited ... that covers guides on how to increase memory power ... memory training method that helps people re-new their entire health ... and beat depression caused by a fatigued mind. In addition, ... razor sharp for a lifetime. The author claimed that this ...
Breaking Medicine News(10 mins):Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2
... of Global Breast Cancer Movement Continues Unprecedented Investment ... Committed to caring for those coping with ... of the disease, Susan G. Komen for the ... announced $60 million in research grants to U.S. ...
... Food Experts HARRY EASTWOOD, ALLISON FISHMAN ... Tiger Aspect Productions Lose the Bulge...but Still ... to have your cake and eat it, too? Lifetime ... that offers viewers the skills and the confidence to give ...
... Lincoln Financial Group (NYSE: LNC ) today ... on its group long-term disability (LTD) insurance product. Lincoln already ... market and -- with the addition of this optional benefit ... insureds overcome family care cost concerns as they try to ...
... REDUCED ETS EXPOSURE , Environmental tobacco smoke (ETS) ... children. However, a new study shows that reducing ... of Alabama researchers followed 240 children with asthma ... asthma therapy. No smoking cessation counseling or ETS ...
... County Health Authority has begun using a web-based ... and enrollment of prospective Medicaid recipients. The new ... health care technology firm based in Norwalk, CT. ... patients to the right assistance program by facilitating ...
... 7 MedPage Today , the only breaking medical ... the challenge posed by the downsizing of newspapers and other ... Today is not only standing firm, but is investigating ... C.E.O. of MedPage Today . The full pledge is ...
Cached Medicine News:Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 2Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 3Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 4Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 5Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 2Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 3Health News:Cook Yourself Thin With Lifetime Television as All-New Culinary Series Teaches Viewers How to Prepare Skinny Alternatives to Their Favorite Foods 4Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 2Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 3Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 4Health News:Journal Chest: April news briefs 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 3Health News:MedPage Today Pledges to Maintain and Expand News Coverage in 2009 2
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... MONTVALE, N.J., Feb. 19 Memory,Pharmaceuticals Corp. ... plans to,conduct a clinical study of MEM 3454, ... biomarkers of schizophrenia, P50 sensory gating and,mismatch negativity, ... formulation and manufacturing activities for MEM 3454, will,be ...
... seven-year, international,study published today finds that some alternative ... better choices for managing,most common neck pain than ... best options for relief are exercises, education, neck,mobilization, ... Therapies such as neck collars and ultrasound are ...
Cached Medicine Technology:Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 2Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 3Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 4Seven-Year Neck Pain Study Sheds Light on Best Care 2Seven-Year Neck Pain Study Sheds Light on Best Care 3
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... on-board capacity of 57 assays ... 146 tests, the CX1000 PRO ... so you can maximize your ... workload. The CX1000 PRO creates ...
When it comes to providing speed, accuracy and menu flexibility, the SYNCHRON CX5 PRO has it all. The state-of-the-art CX5 PRO starts with the wide SYNCHRON chemistry menu to create the ideal full-se...
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance....
Medicine Products: